Bloomberg News

J&J Declines to Comment on U.S. Approval of Sanofi Deal

December 27, 2012

Johnson & Johnson (JNJ:US) and Sanofi (SAN) declined to provide information on a transaction between the two companies that won the approval of U.S. antitrust regulators.

A deal with J&J, its McNeil-PPC, Inc. subsidiary that makes over-the-counter medicines such as Tylenol and personal care products, and Sanofi was authorized by regulators, according to an early termination notice posted today on the Federal Trade Commission (FTC:US)’s website. No details were given by the agency about the transaction.

“We have no additional information and do not comment on pending business development activities,” said Peggy Ballman, a spokeswoman for New Brunswick, New Jersey-based J&J, the world’s biggest maker of health-care products. Marisol Peron, a spokeswoman for Paris-based Sanofi, also declined to comment on the transaction.

“Sanofi certainly has interest in over-the-counter brands, but they’re a small player, especially in the U.S.,” Jeff Jonas, co-portfolio manager of the Gabelli Healthcare & Wellness Trust fund, said in an e-mail. “J&J is constantly reviewing its products/brands and divesting anything that doesn’t have good growth prospects or that they view as non-core.”

Jonas said he doesn’t have any specifics on the deal.

To contact the reporter on this story: Michelle Fay Cortez in Minneapolis at mcortez@bloomberg.net

To contact the editor responsible for this story: Reg Gale at rgale5@bloomberg.net


American Apparel's Future
LIMITED-TIME OFFER SUBSCRIBE NOW

(enter your email)
(enter up to 5 email addresses, separated by commas)

Max 250 characters

Companies Mentioned

  • JNJ
    (Johnson & Johnson)
    • $105.44 USD
    • 0.34
    • 0.32%
  • FTC
    (First Trust Large Cap Growth AlphaDEX Fund)
    • $44.07 USD
    • 0.21
    • 0.47%
Market data is delayed at least 15 minutes.
 
blog comments powered by Disqus